Cyclone® iKure

Louvain-la-Neuve, Belgium, 01 June 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today launches Cyclone^® iKure, a dedicated cyclotron for routine Astatine-211 (At-211) production. Designed for alpha-beam irradiation, this new cyclotron enables radiopharmaceutical manufacturers, research institutions and healthcare providers to accelerate access to targeted alpha therapies with the reliability and quality required for clinical-scale programs.
 

Targeted alpha therapy is emerging as an important area of development in precision oncology. Alpha-emitting isotopes deliver highly concentrated radiation over a very short distance, destroying cancer cells with remarkable precision with limited exposure to surrounding healthy tissue¹. Among alpha emitters, At-211 is attracting attention for its chemical properties and half-life². Yet translating clinical promises into routine patient care has been held back by a fundamental challenge: establishing reliable production infrastructure at scale. With Cyclone^® iKure, IBA aims to address this production challenge.
 

Cyclone^® iKure has been designed specifically for At-211-isotope workflows. It has been engineered to deliver consistent, high-yield At-211 output at production scale. Automated processes simplify daily operations and minimize operator radiation exposure, while a compact footprint allows the system to fit within limited infrastructure, reducing site preparation complexity and cost. The system is designed to meet applicable CE marking requirements, and regulatory compliance.
 

Cyclone^® iKure draws on IBA’s four decades of cyclotron engineering expertise, the same foundation behind the Cyclone^® KIUBE, Cyclone^® IKON and Cyclone^® KEY platforms that serve radiopharmaceutical producers and hospitals worldwide. With this launch, IBA extends its cyclotron portfolio from diagnostic PET & SPECT imaging to therapeutic alpha-isotope production.
 

“Targeted alpha therapy has significant clinical potential, but realizing it at scale depends on reliable and scalable production infrastructure,” said Charles Kumps, President of IBA RadioPharma Solutions. “With Cyclone^® iKure, we are bringing to the alpha-therapy space the precision and dependability that IBA is known for. Designed for routine At-211 production, it is built to help radiopharma innovators and clinicians move from early-stage programs to routine clinical application — and to make targeted alpha therapies accessible to the patients who need them.” 
 

The launch of Cyclone^® iKure reinforces IBA’s commitment to accelerating the bench-to-bedside transition of At-211-labeled drugs. IBA’s strategy rests on three pillars: a purpose-built product, with Cyclone^® iKure enabling routine, industrial-scale At-211 production; ecosystem leadership, through its role as industry co-leader in the ACCELERATE.EU initiative to build the complete European At-211 value chain; and production capacity, through its strategic partnership with Framatome to explore a transatlantic At-211 production network.

¹ Albertsson P et al; Frontiers in Med (2023),9, 1076210: doi:10.3389/fmed.2022.1076210.
² Lindegren et al. EJNMMI Radioph. and Chem. (2026) 11, 15 doi:10.1186/s41181-026-00428-0
 

Hugo Levillain, Anne Royer Moës, Cristiana Gameiro-Paris, Antero Abrunhosa, Tom Deakin, Geraldine Gebhart, Matthias M. Herth, Jean-François Gestin, Ferid Haddad, Andreas Ingemann Jensen, Rebecca Lo Bue, Renata Mikolajczak, Adrian Otamendi, Katie Staunton-Mann, Kevin Tabury & Patrick Flamen on behalf of the Accelerate.EU consortium

Targeted Alpha Therapy (TAT) holds considerable promise for precision oncology, yet its clinical deployment in Europe remains limited. Beyond scientific considerations, progress is constrained by fragmentation across the radiopharmaceutical value chain, encompassing radionuclide production, radiochemistry, preclinical validation, clinical development, regulatory frameworks, infrastructure, and workforce training. 

This webinar will explore the Targeted Alpha Therapy (TAT) workflow, from accelerator-driven production to early clinical use, featuring renowned speakers, Prof Dr Tadashi Watabe from Osaka University, Mrs Clémence Maingueneau, PhD, from Arronax Nantes, and Mr Jean-Michel Geets, IBA Fellow and Domain Principal Expert; and moderated by Mrs Cristiana Gameiro, PhD, IBA Fellow and Domain Expert in radiochemistry.